Selected article for: "disease severity and future study"

Author: Sweeney, Joseph M.; Barouqa, Mohammad; Krause, Gregory J.; Gonzalez-Lugo, Jesus D.; Rahman, Shafia; Gil, Morayma Reyes
Title: Evidence for secondary thrombotic microangiopathy in COVID-19
  • Cord-id: hjkywoge
  • Document date: 2020_10_23
  • ID: hjkywoge
    Snippet: The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with equal distribution of survivors and non-survivors. Patients who died had significantly lower ADA
    Document: The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with equal distribution of survivors and non-survivors. Patients who died had significantly lower ADAMTS13 activity, significantly higher LDH, schistocytes and von Willebrand Factor levels compared to patients discharged alive. Only 30% of patients with an initial ADAMTS13 activity <43% survived vs. 60% with ADAMTS13 ≥43% who survived. In conclusion, COVID-19 may manifest as a TMA-like illness in a subset of hospitalized patients. Presence of schistocytes on admission may warrant a work-up for TMA. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of TMA treatments in COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activity antigen and admission day: 1, 2
    • activity assay and acute inflammation: 1
    • activity level and additional therapy: 1
    • acute inflammation and admission day: 1
    • acute phase response and admission day: 1
    • additional therapy and admission day: 1, 2